Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer

Neil E. Bhola², Maria L. Freilino¹, Sonali C. Joyce¹, Malabika Sen¹, Sufi M. Thomas¹, Anirban Sahu¹, Andre Cassell¹, Ching-Shih Chen³, and Jennifer R. Grandis¹,²

Abstract

G-protein–coupled receptors (GPCR) activate the epidermal growth factor receptor (EGFR) and mediate EGFR-independent signaling pathways to promote the growth of a variety of cancers, including head and neck squamous cell carcinoma (HNSCC). Identification of the common signaling mechanisms involved in GPCR-induced EGFR-dependent and EGFR-independent processes will facilitate the development of more therapeutic strategies. In this study, we hypothesized that phosphoinositide-dependent kinase 1 (PDK1) contributes to GPCR–EGFR cross-talk and signaling in the absence of EGFR and suggests that inhibition of the PDK1 pathway may be effective in the treatment of HNSCC. The contribution of PDK1 to the EGFR-dependent and EGFR-independent signaling in HNSCC was determined using RNA interference, a kinase-dead mutant, and pharmacologic inhibition. In vivo xenografts studies were also carried out to determine the efficacy of targeting PDK1 alone or in combination with the U.S. Food and Drug Administration–approved EGFR inhibitor cetuximab. PDK1 contributed to both GPCR-induced EGFR activation and cell growth. PDK1 also mediated activation of p70S6K in the absence of EGFR. Blockade of PDK1 with a small molecule inhibitor (AR-12) abrogated HNSCC growth, induced apoptosis, and enhanced the antiproliferative effects of EGFR tyrosine kinase inhibitors in vitro. HNSCC xenografts expressing kinase-dead PDK1 showed increased sensitivity to cetuximab compared with vector-transfected controls. Administration of AR-12 substantially decreased HNSCC tumor growth in vivo. These cumulative results show that PDK1 is a common signaling intermediate in GPCR–EGFR cross-talk and EGFR-independent signaling, and in which targeting the PDK1 pathway may represent a rational therapeutic strategy to enhance clinical responses to EGFR inhibitors in HNSCC. Mol Cancer Ther; 11(6); 1–11. ©2012 AACR.

Introduction

G-protein–coupled receptors (GPCR) are 7-transmembrane receptors that mediate various signaling pathways that contribute to growth, survival, and cellular motility. Several GPCR ligands including gastrin-releasing peptide (GRP), prostaglandin E2 (PGE2), bradykinin (BK), and lysophosphatidic acid (LPA) have all been shown to promote the growth of cancers including head and neck squamous cell carcinoma (HNSCC; refs. 1–3). Combined inhibition of GPCRs and epidermal growth factor (EGF) receptor (EGFR) has been further reported to result in improved antitumor effects in HNSCC (2, 4). However, due to the heterogeneous expression of GPCRs in HNSCC, targeting of multiple GPCRs and EGFR is impractical in the clinical setting. Identification of a common signaling intermediate downstream of GPCR signaling that is amenable to inhibition may represent a plausible therapeutic strategy.

We previously reported that GRP mediated the release of EGFR ligands in a phosphoinositide-dependent kinase 1 (PDK1)–dependent manner through phosphorylation of TNF-α-converting enzyme (TACE; ref. 5). Furthermore, downmodulation of PDK1 expression combined with erlotinib resulted in improved antiproliferative and anti-invasive effects (5). We recently showed that GPCRs induce p70S6K activation in an EGFR-independent setting, where combined inhibition of p70S6K and EGFR resulted in decreased growth in vitro and in vivo (6). PKD1 is a serine/threonine kinase that has been shown to activate multiple kinases from the AGC (protein kinase A, protein kinase G, protein kinase C) family of kinases that also includes p70S6K, PKB/Akt, and p21-activated kinase (PAK; ref. 7). The pleiotropic capacity of PDK1...
makes it a promising molecular and therapeutic target for HNSCC. In this study, we investigated the contribution of PDK1 in pathways mediated by several GPCR agonists detected in HNSCC, including PGE2, BK, and LPA. In addition, we assessed the contribution of PDK1 in activating EGFR-independent signaling. The contribution of PDK1 was tested using several approaches including siRNA, expression of a dominant-negative construct, and pharmacologic inhibition, alone and in combination with EGFR blockade. Our results validate PDK1 as a therapeutic target in which strategies that target the PDK1 pathway may enhance EGFR blockade in HNSCC, in which EGFR inhibition is an established therapeutic strategy.

Materials and Methods

Cell lines

All the HNSCC cell lines (PCI-37A, 1483, PCI-6B, UM-22A, UM-22B, and UMSCC-1) were of human origin. 1483 cells were derived from an oropharyngeal tumor, UM-22B and PCI-6B cell lines were derived from metastatic lymph nodes, and PCI-37A and UM-22A were from a primary tumor arising in the epiglottis (8). UMSCC-1 cells were derived from squamous cell carcinoma of the oral cavity. Cells were maintained in Dulbecco’s Modified Eagle’s Medium with 10% heat-inactivated fetal calf serum (Invitrogen) at 37°C with 5% CO2. All cell lines were validated and stained with trypan blue solution before being counted. MTT assays were carried out by adding the MTT reagent to the cells and incubated for 2 hours at 4°C on a rotary shaker. Forty microliters of Protein G agarose beads (Upstate) were added to the lysates and allowed to incubate for 2 hours at 4°C on a rotary shaker. The beads were collected by centrifugation at 4°C, 14,000 rpm for 1 minute. The beads were resuspended in 30 μL of lysis buffer and 8 μL of 4× loading dye and boiled for 10 minutes at 95°C, followed by Western blot analysis. The immunoprecipitated proteins were then resolved on an 8% SDS-PAGE gel. After being transferred onto a nitrocellulose membrane, the membrane was blocked in 5% milk and blotted with the antiphosphotyrosine antibody PY99 (Santa Cruz Biotechnology) at 1:500 in 5% milk dissolved in TBST solution [0.9% NaCl, 0.5% Tween 20, and 50 mmol/L Tris (pH 7.4)]. After washing 3 times with TBST solution, the membrane was incubated with the secondary antibody (goat antirabbit/mouse IgG–horseradish peroxidase conjugate; Bio-Rad Laboratories) by autoradiography. Blots were stripped in Restore Western Blot Stripping buffer (Fierce) for 15 minutes at room temperature, blocked for 1 hour, and reprobed with EGFR antibody (Transduction Laboratories) at 1:500 dilution. Whole cell lysates were also resolved on 8% SDS-PAGE, transferred to nitrocellulose, and probed for PDK1 (Cell Signaling), and β-tubulin (Abcam).

siRNA transfection

PDK1 siRNA was designed to target the following sequence: 5’-CUGGAACCCAGAGAA-3’ and obtained from Dharmacon. A total of 2 × 106 cells were seeded in 10-cm plates and allowed to incubate overnight at 37°C. Cells were transfected with siRNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

Cell viability assays

HNSCC cells were seeded and incubated overnight at 37°C. Cells were treated with inhibitors or transfected with siRNA for different time points. Cells were trypsinized and stained with trypan blue solution before being transferred to a hemocytometer and viable cells were counted. MTT assays were carried out by adding the MTT solution (Sigma-Aldrich) for 30 minutes at 37°C. MTT solution was removed, followed by addition of dimethyl sulfoxide (DMSO) solution. The resulting formazan product was read at 595 nm using the uQuant Microplate spectrophotometer. Graphs were plotted using the GraphPad Prism Software.

Xenograft studies

All animal studies were done according to the University of Pittsburgh Institutional Animal Care and Use Committee. Athymic nude mice were subcutaneously
inoculated with UM-SCC1, 1483VC, or 1483 PDKM cells. Following observation of palpable tumors, xenografts were randomized into treatment groups. For AR-12 experiments, mice were randomized into 4 groups (i) vehicle, (ii) AR-12 (100 mg/kg daily p.o), (iii) C225 (0.2 mg i.p 3 times/wk) and (iv) AR-12+C225. For the PDKM experiments, nude mice (n = 5 per group) inoculated with 1483VC and 1483 PDKM were treated with either vehicle or C225 (0.8 mg i.p 3 times/wk). Tumors and mouse weights were measured 3 times per week. Tumor volume was calculated with the following formula: length/2 x width^2.

Results

PDK1 contributes to EGFR phosphorylation by several GPCR ligands

We previously reported that GRP stimulates the release of the EGFR ligand amphiregulin via PDK1-mediated TACE phosphorylation (5). To determine whether PDK1 is a common signaling intermediate in the activation of EGFR by other GPCR ligands, we examined the effect of PDK1 knockdown on GPCR-induced phosphorylation of EGFR. We used 3 HNSCC cell lines: PCI-37A, UM-22A, and PCI-6B. These HNSCC cell lines were treated with 3 different GPCR ligands, PGE2, BK, or LPA followed by assessment of EGFR tyrosine phosphorylation. PGE2, BK, and LPA have previously been shown to phosphorylate EGFR in several HNSCC cell lines in addition to the HNSCC models shown here (1–3). PGE2 and BK-mediated phosphorylation of EGFR was significantly abrogated in HNSCC cells transfected with PDK1 siRNA (Fig. 1A and B; P = 0.048). LPA-mediated phosphorylation of EGFR was also reduced by PDK1 downmodulation (Fig. 1C; P = 0.0001). These findings suggested that PDK1

Statistics

The differences between treatment groups in biochemical assays were determined by 2-tailed Student t test. The differences between treatment groups in xenograft experiments were determined using the exact Wilcoxon–Mann–Whitney 1-sided test. A P value less than 0.05 was considered to be statistically significant.
broadly contributes to GPCR-mediated EGFR transactivation in HNSCC.

**PDK1 contributes to GPCR-induced proliferation**

We and others have reported that GPCR ligands induce HNSCC proliferation (1, 2). To determine the role of PDK1 in GPCR-stimulated cell growth, HNSCC cells were transfected with control or PDK1 siRNA for 48 hours followed by 24-hour stimulation with PGE2 or BK. PGE2 or BK (Fig. 1D) induced an approximately 20% increase in growth of control siRNA-transfected cells. However, in PDK1 siRNA-transfected cells, PGE2 or BK-mediated growth was abrogated to 8% and 5%, respectively ($P = 0.046, P = 0.007$). In UM-SCC1 cells, BK induced a 20% increase in growth. However, in the presence of PDK1 siRNA, BK failed to augment growth (Supplementary Fig. S1; $P = 0.003$). These results indicated that PDK1 plays a role in GPCR-mediated proliferation of HNSCC cells.

**PDK1 kinase activity contributes to GPCR signaling and HNSCC growth**

Kinase inhibitors have emerged as potential cancer treatment strategies in tumors that show increased activation of oncogenic kinases. To determine the effect of PDK1 kinase inactivation, HNSCC cells (UM-22A) were transiently transfected with the PDK1 kinase-dead mutant (9) resulting in abrogation of PGE2-induced growth compared with vector-transfected control cells (Supplementary Fig. S2; $P = 0.04$). A HNSCC cell line (1483) was stably transfected with the kinase-dead PDK1 construct (PDKM) or control vector (VC). We validated expression of the kinase-dead mutant by assessing expression of the myc tag in 2 representative clones (Fig. 2A). Next, we treated the control and kinase-dead PDK1 mutant-transfected cells with BK followed by assessment of EGFR phosphorylation. As shown in Fig. 2B, EGFR phosphorylation was not induced by BK in the PDKM cells compared with a 2-fold increase in EGFR phosphorylation detected in the vector-transfected control cells. Next, we assessed the proliferation of the PDKM cells compared with the control cells under normal growth conditions. As shown in Fig. 2C, the proliferation rate of 1483 PDKM cells was reduced compared with vector-transfected control cells after 4 days. These results indicated that PDK1 kinase activity contributes to HNSCC growth and GPCR-induced EGFR phosphorylation.

**PDK1 mediates EGFR-independent signaling in HNSCC**

GPCRs have been reported to induce signaling via both EGFR-dependent and EGFR-independent mechanisms. We recently showed that GPCR ligands induce
EGFR-independent effects via the robust activation of p70S6K (6). PDK1 has been reported to activated p70S6K in AKT-dependent and AKT-independent manners (11). To determine whether PDK1 activation was exclusively downstream of EGFR in HNSCC, we examined the phosphorylation of p70S6K in the presence of siRNAs targeting EGFR and/or PDK1. EGFR siRNA induced p70S6K phosphorylation as previously reported (6), however in the presence of PDK1 siRNA, p70S6K phosphorylation was significantly abrogated (Fig. 3A; \( P < 0.02 \)). Similar to the results observed with PDK1 siRNA, EGFR siRNA failed to induce p70S6K phosphorylation in PDKM cells (Fig. 3B). These results suggested that PDK1 can mediate mitogenic signaling via EGFR-dependent and EGFR-independent routes.

**Pharmacologic inhibition of the PDK1 pathway abrogates HNSCC growth, AKT phosphorylation, and cyclin D1**

Given the central role of PDK1 in both EGFR-dependent and EGFR-independent signaling, we next sought to evaluate the efficacy of pharmacologic inhibition of the PDK1 pathway using the small molecule inhibitor AR-12 (Fig. 4A). AR-12 is a celecoxib derivative with no activity against COX-2 (12). HNSCC cell lines displayed a range of \( IC_{50} \) values from 74 to 820 nmol/L (Fig. 4B and Supplementary Table S1). In contrast, inhibition of the normal mucosal epithelial cell line Het-1A required higher concentrations of AR-12 (\( IC_{50} = 6 \mu mol/L \)). The effects of AR-12 was previously reported in oral cancer cells in vitro (13). To determine the *in vivo* efficacy of AR-12, HNSCC (UMSCC-1) cells were inoculated subcutaneously in athymic nude mice. After the formation of palpable tumor nodules 7 days later, mice were assessed PARP cleavage and expression of the antiapoptotic molecule survivin in treated HNSCC cells. AR-12 induced significant tumor regression as early as day 5 (Fig. 4C; \( P < 0.001, \) day 28). No toxicities were observed as measured by body weight analysis. To assess the biochemical effects of AR-12, we assessed cell lines for levels of Akt phosphorylation, which can serve as an indicator of PDK1 activity (14). AR-12 (1 \( \mu mol/L \)) abrogated phoshpo-Akt (T308 and S473) expression levels in both HNSCC cell lines examined (Fig. 4D). We next investigated the role of PDK1 as an AR-12 target by carrying out dose–response studies in PDK1 siRNA and control siRNA-transfected HNSCC cells. PDK1 siRNA-transfected cells displayed greater \( IC_{50} \) values compared with control siRNA-transfected cells (Supplementary Fig. S3). These observations indicated that PDK1 expression contributed to HNSCC sensitivity to AR-12.

**AR-12 induces apoptotic signaling pathways in HNSCC cells**

To determine whether the decreased growth rate induced by AR-12 was due to increased apoptosis, we assessed PARP cleavage and expression of the antiapoptotic molecule survivin in treated HNSCC cells. AR-12—
induced PARP cleavage was observed at 300 nmol/L and 1 μmol/L concentrations in PCI-37A and UM-22B cells, respectively (Fig. 5A). In contrast, AR-12 failed to induce apoptosis in the Het-1A normal mucosal epithelial cell line (Fig. 5B). In addition to PARP, we examined the effect of AR-12 on survivin expression. Survivin is a member of the inhibitor of apoptosis family of proteins, which is involved in mediating cell proliferation and inhibiting apoptosis (17,18). AR-12 decreased survivin expression at 100 nmol/L and 1 μmol/L concentrations in PCI-37A and UM-22B cells, respectively (Fig. 5C). Terminal deoxyribonucleotidyl transferase–mediated dUTP nick end labeling analysis of vehicle- and AR-12–treated xenografts displayed no significant differences in apoptosis between treatment groups (data not shown). However, in the absence of serial determinations of apoptosis, it is possible that assessment of a dynamic process at a single 4-week time point may not be sensitive enough to assess the mechanism of reduced growth. These results indicated that the pharmacologic inhibition of PDK1 with AR-12 induces apoptosis by increasing PARP cleavage and decreasing expression of the antiapoptotic marker survivin.

**Targeting PDK1 enhances the antiproliferative effects of EGFR inhibition**

Because PDK1 mediates both EGFR-dependent and EGFR-independent signaling pathways, we determined the efficacy of PDK1 targeting in combination with EGFR inhibition strategies. To determine whether AR-12 treatment increased HNSCC sensitivity to EGFR inhibition, we first examined the effects of AR-12 in combination with the preclinical EGFR TKI, AG1478 or the clinical EGFR TKI, erlotinib. As shown in Fig. 6A, combined treatment with sub-IC50 concentrations of each compound resulted in enhanced cell growth inhibition compared with either agent alone (P < 0.0001). HNSCC cells have been shown to release GPCR ligands BK and PGE2 into the tumor microenvironment (19, 20). Therefore, we next used an *in vivo* HNSCC model, in which the autocrine and paracrine secretion of the GPCR ligands contributes to tumor growth. We used the EGFR monoclonal antibody cetuximab (C225), which was U.S. Food and Drug Administration approved, in 2006 for the treatment of HNSCC. As shown in Fig. 6B, C225 treatment of HNSCC xenografts expressing kinase-dead PDK1 (PDKM1) resulted in decreased tumor growth compared with cetuximab treatment of vector control (VC) xenografts (P = 0.048). Interestingly, vehicle-treated PDKM xenografts and C225-treated VC xenografts displayed increased tumor growth compared with vehicle-treated VC xenografts and C225-treated PDKM xenografts. In an attempt to determine the mechanism of enhanced tumor growth, we carried out immunoblot analysis of vehicle and C225-treated xenografts. Decreased phospho-Akt was observed in PDKM xenografts, however, expression of phospho-Akt (T308) was increased in vehicle-treated xenografts. Decreased phospho-Akt was observed in PDKM xenografts, however, expression of phospho-Akt (T308) was increased in vehicle-treated xenografts.
MAPK (mitogen-activated protein kinase) was only abrogated in the C225-treated PDKM xenografts compared with vehicle-treated xenografts (Supplementary Fig. S5). Additional investigation showed that the antitumor effects of combined treatment with C225 and AR-12 was not significantly different compared with treatment using either agent alone (Fig. 6C). Because both AR-12 and C225 are highly potent in these HNSCC xenograft models, we were likely unable to observe a combined effect. These results suggested that inactivation of PDK1 kinase activity may enhance the efficacy of EGFR inhibitors in preclinical HNSCC models. Furthermore, inactivation of PDK1 kinase may not be sufficient to abrogate HNSCC tumor growth due to persistent MAPK phosphorylation, which can be abrogated by EGFR inhibition.

Discussion

GPCR–EGFR cross-talk has been shown to mediate tumorigenesis in a variety of cancer models via the extracellular release of EGFR ligands and EGFR-independent signaling (1, 21–28). Although the combined targeting of GPCRs and EGFR shows additive or synergistic growth suppression effects, it is impractical to target multiple GPCRs and EGFR in the clinical setting. Identification of a common “druggable” signaling intermediate may represent a more rational cotargeting strategy to target GPCR and EGFR-mediated tumor progression. We previously reported that PDK1 mediated EGFR ligand release in response to GRP stimulation (5). PDK1 downmodulation also enhanced EGFR inhibition of proliferative and invasion. In this study, we show that PDK1 represents a common signaling mediator of GPCR-mediated EGFR-dependent and EGFR-independent signaling in HNSCC. Furthermore, we show that targeting PDK1 expression and activity abrogated GPCR-mediated growth and enhanced EGFR inhibition in HNSCC preclinical models.

Previous studies showed that GPCR ligands mediate release of EGFR ligands in a Src and matrix metalloproteinase–dependent manner (1, 5, 29–31) in multiple HNSCC cell line models. We first reported the contribution of the phosphoinositide 3-kinase (PI3K)–PDK1 signaling complex in the release of EGFR ligands in HNSCC mediated by the bombesin, GRP. Here, we observed that PDK1 contributed to PGE2, BK, or LPA-mediated phosphorylation of EGFR. PGE2, BK, and LPA specifically mediate the EGFR phosphorylation via activation of EP, B2R, and LPA1 receptors, respectively (1, 19, 20). We have also reported that PGE2 and BK-mediated release of TGF-\(\alpha\) was abrogated with TACE siRNA (2). Taken together, these cumulative results suggest that PDK1-mediated TACE phosphorylation seems to be critical for PGE2-, BK-, and LPA-mediated EGFR phosphorylation and oncogenic signaling. In addition to EGFR ligands (32), TACE has been shown to mediate the release of heregulin, leading to activation of HER3 (33). Targeting the release of these autocrine ligands via PDK1 inhibition may have therapeutic benefits over a broader range of tumor types.

PDK1 is a pleiotropic kinase that mediates proliferative, invasive, and survival signaling pathways via activation of multiple substrates (7). We previously reported that PDK1 downmodulation decreased HNSCC...
growth (5), however, studies to date have not investigated the contribution of PDK1 in specific GPCR-mediated growth in any cancer. Using PDK1 siRNA, we found that GPCR-mediated growth was inhibited in HNSCC. Blockade of EGFR has been shown to significantly abrogate GPCR-mediated growth and invasion (2). This study corroborates our earlier findings that GPCRs partially mediate HNSCC growth via EGFR ligand release and consequent EGFR activation (2). However, we observed that PDK1 mediated both EGFR-dependent and EGFR-independent signaling. GPCRs therefore most likely mediate HNSCC growth via both EGFR ligand release as well as EGFR-independent activation of p70S6K. We also observed that growth of PDKM cells was abrogated compared with control cells although PDK1 siRNA, and PDKM displayed contrasting effects on phospho-Akt (Supplementary Fig. S6). Because these cells were cultured in serum containing media, it would suggest that the partial growth inhibition was due to serum factors inducing EGFR-mediated growth. Interestingly, we did not observe the similar phenotype in vivo. PDKM xenografts showed sustained levels of p-MAPK, which was diminished in C225-treated PDKM xenografts. Inhibition of MAPK activity by EGFR inhibitors was shown to improve the antitumor efficacy of breast cancer cells forced to express the PI3K inhibitor PTEN (34). Furthermore, monotherapeutic PDK1 inhibition was reported to increase MAPK phosphorylation levels and ineffectively prevent tumor inhibition in transgenic mouse models (35). The sustained activation of MAPK in PDKM cells may create an enriched tumor promoting microenvironment in vivo compared with in vitro conditions.

Although we have shown that PDK1 mediates GPCR stimulated growth via EGFR activation, PDK1 may contribute to GPCR-mediated growth in the presence of EGFR blockade. We and others have reported that PGE2 and BK mediate mitogenic signaling in the presence of EGFR inhibitors (2, 36). In non–small cell lung carcinoma (NSCLC) and an ovarian cancer cell line, PGE2 and BK mediated EGFR-independent signaling via PI3K and PKC (36–38). PI3K is upstream of PDK1 and PKC is also a PDK1 substrate (7, 39). Here, we show that PDK1 siRNA decreased p70S6K

Figure 6. PDK1 targeting enhances EGFR inhibition in HNSCC. A, UM-22B cells were treated with AR-12 (200 nmol/L), AG1478 (6 μmol/L), or erlotinib (7 μmol/L) or a combination of AR-12 plus AG1478 or erlotinib. MTT assay was carried out after 72 hours and the data analysis was done using GraphPad Prism Software. Experiments were conducted 3 times in 6 replicates (P = 0.003). B, athymic nude mice (n = 5) were inoculated with 1.5 × 10⁷ PDK1 kinase-dead transfected HNSCC cells (PDKM) or vector-transfected control cells (VC) in the left and right flanks, respectively. After the formation of tumor nodules (7 days later), mice were treated with vehicle (saline) or cetuximab 3 times a week (0.8 mg i.p.) in conjunction with tumor volume determinations. C, athymic nude mice were inoculated with UM-SCC1 cells. After 7 days, mice were randomized into 4 treatment groups shown (i) vehicle, (ii) AR-12, (iii) C225, and (iv) AR-12 + C225. Tumors were measured every 3 days and tumor volume was calculated (length/2 × width²). Tumor volumes were graphed using Graph Pad prism Software.
phosphorylation induced by EGFR downmodulation. Furthermore, we reported that EGFR downmodulation increased PKCδ activation, and PKCδ siRNA decreased p70S6K phosphorylation (6). Therefore, GPCR-mediated activation of PDK1 may also have phenotypic implications independent of EGFR ligand release.

Celecoxib has been shown to inhibit Akt activity via blockade of PDK1 (40, 41). AR-12 is a celecoxib derivative that was reported to inhibit PDK1 activity in different cell models (10). However, in some cancer models, AR-12 also showed cytotoxic effects via PDK1-independent pathways (12, 42–44). AR-12 was reported to activate CDKs and mediate oral cancer apoptosis in a p21-dependent manner (13). In this study, we observed that AR-12 abrogated Akt phosphorylation. However, AR-12 also down-modulated cyclin D1 expression and induced PARP cleavage at much lower concentrations. These cumulative findings indicate that AR-12 induces cell death in HNSCC via multiple mechanisms. One report showed that AR-12 had a greater affinity for the PDK1 substrate, p21-activated kinase 1 (PAK1) than for PDK1 itself. Structurally, AR-12 was found to bind to the ATP binding pocket of PAK1 (45). Therefore, the enhanced sensitivity of HNSCC cells to AR-12 may be due to its ability to inhibit other AGC kinases with a greater affinity, suggesting that this compound is a PDK1 pathway inhibitor. Alternatively, PDK1 may inhibit HNSCC cell proliferation and induce apoptosis through its effects on substrates other than Akt. To further delineate the efficacy of pharmacologic PDK1 inhibition, use of more novel and specific inhibitors should be investigated (46).

Combined targeting of GPCRs and EGFR has shown improved antitumor effects in many preclinical cancer models, including HNSCC (2, 4, 47, 48). Approximately 50% of new drugs developed target GPCRs, hence emphasizing their importance in treating human disease. The autocrine/paracrine release of TGF-α was reported to correlate with poor HNSCC patient prognosis (49). Therefore, inhibition of EGFR ligand release by both GPCR and EGFR-mediated activity represents a potential treatment strategy. In addition to abrogating PDK1-mediated activation of proliferative and motility effectors such as p70S6K and PAK1, inhibition of TACE-mediated release of TGF-α mediated by FGE2 and BK may enhance the inhibitory efficacy of EGFR blockade and its consequent autocrine release of EGFR ligands. In this study, we found that the pharmacologic inhibitor AR-12 enhanced EGFR TKI inhibition, at least in part, through PDK1 targeting. AR-12 has also been reported to enhance the antitumor efficacy of erlotinib in NSCLC (44). Furthermore, after observing that PDK1 can mediate mitogenic signaling in the absence of EGFR, the enhanced efficacy of PDK1 and EGFR inhibition in vitro may be due to combined inhibition of independent pathways. Upregulation of IGF1R, which also signals via PDK1–PI3K pathway, has been reported to contribute to EGFR TKI resistance in HNSCC (50). Therefore inhibition of a common downstream RTK mediator such as PDK1 will potently enhance EGFR inhibition strategies. However, it must be noted that we did not observe a combined effect with AR-12 and cetuximab in vivo, most likely due to the potent efficacy of AR-12 administered as a single agent. Due to its reported PDK1-independent effects, it is also possible that AR-12 potently suppresses both EGFR-dependent and EGFR-independent signaling cascades to induce tumor regression. Although EGFR is a proven therapeutic target in HNSCC, only a subset of patients will respond to EGFR inhibitors. Targeting PDK1 by inhibition of its kinase activity or expression is a viable therapeutic option for HNSCC patients to enhance the effects of EGFR blockade.

Disclosure of Potential Conflicts of Interest
C.-S. Chen has ownership interest (including patents) in Arno Therapeutics.

Grant Support
The work received support from NIH grants P50CA097190 and R01CA098372 and the American Cancer Society Clinical Research Professorship (J.R. Grandis).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 16, 2011; revised March 24, 2012; accepted March 29, 2012; published OnlineFirst April 5, 2012.

References


25. Mo/tools/56021f8c-5b6d-45e9-940d-70c6b7b28e3e. Downloaded from mct.aacrjournals.org on April 28, 2017. © 2012 American Association for Cancer Research. Mol Cancer Therapeutics
Molecular Cancer Therapeutics

Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer

Neil E. Bhola, Maria L. Freilino, Sonali C. Joyce, et al.

Mol Cancer Ther Published OnlineFirst April 5, 2012.

Updated version Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-11-0936

Supplementary Material Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2012/04/05/1535-7163.MCT-11-0936.DC1

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.